Bioatla Earnings Reports

BioAtla reported a net loss of $18.7 million for Q2 2025, an improvement from the $21.1 million loss in the same quarter last year. The company saw reduced operating expenses, primarily due to workforce reductions and program prioritization. Cash and cash equivalents decreased significantly to $18.2 million, but the company is actively pursuing cash preservation measures and partnership opportunities.

BioAtla reported a net loss of $15.3 million for Q1 2025, an improvement from the $23.2 million net loss in Q1 2024. This was primarily driven by a decrease in research and development expenses, which fell to $12.4 million from $18.9 million in the prior year, as the company completed Phase 2 trials and focused on prioritized programs. The company's cash balance is projected to fund operations beyond key clinical readouts in 1H 2026.

BioAtla announced a substantial decrease in net loss for Q4 2024, down to $14.9 million from $26.9 million in Q4 2023, driven by reduced R&D and G&A expenses. The company also highlighted encouraging clinical outcomes across its CAB platform programs and extended its financial runway into 1H 2026 through cost-reduction measures.

BioAtla reported a net loss of $10.6 million for Q3 2024, including $11.0 million in collaboration revenue. The company's cash and cash equivalents were $56.5 million as of September 30, 2024, expected to fund operations into early 2026. They are advancing clinical programs and received positive FDA feedback, positioning them for potential registrational trials in 2025.

BioAtla reported its Q2 2024 financial results, with a net loss of $21.1 million. The company's cash and cash equivalents were $61.7 million as of June 30, 2024, expected to fund operations through Q3 2025. Key clinical programs are progressing, including ozuriftamab vedotin receiving Fast Track Designation from the FDA.

BioAtla reported a net loss of $23.2 million for the first quarter ended March 31, 2024, compared to a net loss of $27.5 million for the same quarter in 2023. The company's cash and cash equivalents were $80.6 million as of March 31, 2024, expected to fund operations into the second half of 2025.

BioAtla reported its Q4 and full year 2023 financial results, highlighting progress in its CAB-ADC clinical trials and CAB-CTLA-4 clinical asset. Key milestones include cleared DLT observation period for BA3071, fully enrolled Phase 2 trials for BA3021, and progress in the Phase 2 study for BA3011. The company's cash balance is expected to fund operations into 2H 2025.

BioAtla reported its Q3 2023 financial results, highlighting clinical progress with CAB-AXL-ADC (BA3011) and CAB-ROR2-ADC (BA3021), and the initiation of a Phase 2 study for CAB-CTLA-4 (BA3071). The company's cash balance is expected to fund operations into the second half of 2025.

BioAtla reported a net loss of $35.8 million for the second quarter of 2023, compared to a net loss of $28.9 million for the same quarter in 2022. The company's cash and cash equivalents were $168.7 million as of June 30, 2023, expected to provide funding into 2025.

BioAtla reported a net loss of $27.5 million for the first quarter ended March 31, 2023, compared to a net loss of $24.3 million for the same quarter in 2022. The company's cash and cash equivalents were $192.7 million as of March 31, 2023, which is expected to fund planned operations into 2025.

BioAtla reported a net loss of $27.5 million for the quarter ended December 31, 2022, compared to a net loss of $23.4 million for the same quarter in 2021. Cash and cash equivalents were $215.5 million as of December 31, 2022.

BioAtla's CAB-ADC programs showed encouraging data, with multiple partial responses observed in the Phase 2 NSCLC study. The company anticipates several updates in the coming months as they progress BA3021 and BA3071. BioAtla has a strong cash position expected to last into the second half of 2024.